MOTS-c and NAD+ together restore the cellular adaptation loop that metabolic stress and age erode. MOTS-c, often referred to as an 'exercise mimetic', is a peptide encoded in mitochondrial DNA that tells cells to build new mitochondria and shift toward fat as fuel — the same signal endurance exercise produces. NAD+ is the electron-carrier currency cells need to execute those instructions: ATP production, stress-response gene changes (SIRT1⁵), DNA repair. Paired, they close the loop at both ends.
Plasma NAD+ falls roughly 80% between age 20 and 60. MOTS-c levels track inversely with insulin resistance — the people with the most metabolic flexibility have the most MOTS-c, and levels erode under the same conditions that drive age-related disease. In obese middle-aged adults, an oral NAD+ precursor (nicotinamide riboside) raised NAD+ levels but failed to improve insulin resistance or other metabolic endpoints — substrate without the adaptive signal to act on it (Pencina 2023, JCEM⁶). The mechanistic case for pairing is exactly this gap: cells need both the adaptive signal and the currency to act on it.
This protocol is built for populations whose adaptation loop is under pressure: adults with unexplained fatigue, GLP-1 users feeling the energy drag side-effect, patients with post-viral or long-COVID energy collapse — and active individuals hitting a ceiling with training, or feeling their energy capacity is beginning to slip away. What these share is a broken adaptation loop — the signal weakening, the substrate depleting, or both.
| At a Glance | |
|---|---|
| Dosage | NAD+ 100–200 mg IM or SubQ, 3–5× per week. MOTS-c 5–10 mg SubQ, 2–3× per week. |
| Protocol | 12 weeks, three phases (loading / build / maintain). Morning NAD+; MOTS-c 30–60 min before zone-2 cardio. |
| Results timeline | NAD+ substrate replacement shifts felt energy within 1-2 weeks, sometimes within days; MOTS-c effects can be felt immediately, persisting for 72 hours — hence the split dosing. |
| Side effects | SubQ and IM injections of both compounds can sting — isotonic BAC water and slower push rates reduce this. |
| Regulatory status | Neither injectable NAD+ nor MOTS-c is FDA-approved for energy or metabolic indications. Oral NAD+ precursors: nicotinamide riboside (NR) is FDA GRAS; nicotinamide mononucleotide (NMN) regulatory status in the US is evolving. |
| Best stacked with | Semaglutide, Tirzepatide, Retatrutide for GLP-1 energy drag support. L-Carnitine for fatty acid transport into mitochondria. |
The NAD+ and MOTS-c Stack
Two mechanistic findings anchor the pairing directly.
MOTS-c raises the ceiling on NAD+ recycling. Cells constantly recycle NAD+ — enzymes break it down, the salvage pathway rebuilds it. The rate-limiting enzyme in that rebuild is upregulated by MOTS-c (NAMPT upregulation², Wan 2023). MOTS-c raises the ceiling but doesn't create NAD+ from nothing — it accelerates recycling of whatever NAD+ is present. Supplemental NAD+ answers the substrate side of that equation.
SIRT1 converts the signal only when NAD+ is available. The enzyme that translates MOTS-c's signal into gene-expression changes (SIRT1⁵) requires NAD+ on hand to function. In depleted cells, the MOTS-c signal arrives but can't fully land — SIRT1 sits inactive without its cofactor. Co-administration is how the signal converts to adaptation.
For the single-compound mechanisms in depth, see the NAD+ guide and MOTS-c guide.
Who Benefits Most
The adaptation loop erodes at the signal end, the substrate end, or both. Identifying where the deficit sits predicts response.
Signal-side erosion. MOTS-c production declines with sedentary living, chronic metabolic stress, and age — but the decline correlates more with phenotype than with chronology. A 55-year-old who trains consistently and sleeps well often has MOTS-c levels that outperform a 32-year-old under chronic stress. The mechanism question is whether cellular demand is regularly signaling for adaptation; in sedentary patterns or compressed recovery windows, it isn't.
Substrate-side erosion. NAD+ depletes faster under inflammation and oxidative stress (e.g., illness, alcohol, sleep-deprivation), caloric deficit (when cells burn fat, each step of fat-to-ATP conversion consumes NAD+), and age (plasma NAD+ falls ~80% between 20 and 60). Substrate-side collapse is why acute post-viral fatigue and aggressive fat-loss protocols hit the loop hardest — the cell has the signal but not the currency.
Four phenotypes present this pattern clinically
Adults with unexplained fatigue. The pattern is chronic — energy degrades over months, recovery lengthens, training or cognitive load that used to be sustainable now isn't. Baseline workup is clean. What's usually present is substrate-side erosion with signal-side decline in the background. NAD+ substrate replacement produces a felt shift almost immediately; MOTS-c builds and extends capacity across the rest of the cycle.
GLP-1 users experiencing energy drag. Semaglutide, tirzepatide, and retatrutide all drive aggressive fat mobilization and a steep caloric deficit. Converting that mobilized fat to ATP consumes NAD+ at every step of the fat-burning pathway (beta-oxidation). The loop gets stressed on both ends — the GLP-1 signals massive fuel-source change while NAD+ demand rises sharply against a baseline that was already declining.
Retatrutide adds a third receptor (glucagon) that directly tells the liver to burn more fat, which increases the NAD+ draw on the liver specifically. See the GLP-1 fatigue guide for the underlying mechanism and the retatrutide + NAD+ protocol for a retatrutide-specific implementation.
Patients with post-viral or long-COVID energy collapse. Viral illness drives acute NAD+ depletion through two competing demands: DNA-repair machinery kicks into overdrive, and immune cells burn through NAD+ to sustain inflammatory signaling. The loop collapses on the substrate side first, often with secondary signal-side erosion as deconditioning follows. Injectable NAD+ tends to produce the fastest felt effect in this phenotype — the acute deficit closes quickly. MOTS-c adds capacity-building over weeks as activity tolerance returns.
Active individuals hitting a ceiling with training. High-volume training accelerates both ends of the loop — MOTS-c production rises with demand, NAD+ consumption rises with the metabolic work. The ceiling people describe is usually the signal or substrate capacity catching up with the work they're producing. The pair raises both ceilings in parallel.
Non-responders
Primary cause is sleep deprivation or untreated thyroid dysfunction — neither compound fixes either, and response will feel absent. Advanced mitochondrial disease is a different problem than signal-and-fuel deficit. A rare genetic variant in MOTS-c (K14Q³) weakens the peptide's ability to bind its downstream target and may blunt response; clinical testing for the variant isn't yet routine.
Protocol
NAD+ is administered intramuscularly (IM) or subcutaneously (SubQ). MOTS-c is administered subcutaneously. The protocol runs 12 weeks, phased across loading, build, and maintenance.
| Phase | MOTS-c | NAD+ | Training / Lifestyle |
|---|---|---|---|
| Loading (weeks 1–2) | 10 mg SubQ 3× per week | 150–200 mg IM or SubQ, daily to 5× per week | Electrolytes, zone-2 cardio |
| Build (weeks 3–6) | 5–10 mg SubQ 2–3× per week | 150 mg IM or SubQ 4× per week | Resistance training, protein ≥ 1.6 g/kg |
| Maintain (weeks 7–12) | 5–10 mg SubQ 2× per week | 100–150 mg IM or SubQ 3× per week | Sleep 7–9 hrs, glycine before bed |
Route practicalities. NAD+ IM tolerates higher doses per injection with less site discomfort; SubQ is easier for self-administration but can sting — using pH buffered NAD+, isotonic bacteriostatic water with sodium chloride (NaCI), and slower injection push rates reduce this. MOTS-c SubQ is standard — but also benefits from isotonic BAC water with NaCI. Split injections across two sites.
Sequencing. Most readers run both compounds from week one. If NAD+ depletion is clearly acute — post-viral collapse, post-illness, recent high-dose GLP-1 titration — loading NAD+ one-week prior to starting MOTS-c is mechanistically defensible. This is a personal or clinical judgment.
Oral precursors are the secondary route. NMN or NR work as a maintenance layer after injectable loading, or for patients who won't inject at all — not as a replacement during an active loading phase. Doses in the FAQ; full oral-vs-injection trade-off in the NAD+ guide.
Cycling. A 4-week washout after the 12 weeks is common, but not required — continuous maintenance at the Maintain-phase cadence is also documented, especially for sustained GLP-1 support.
Reconstitute correctly — see the reconstitution guide and peptide dosing calculator. MOTS-c at these doses is investigational; no published human RCT has tested this exact protocol. The dose range is anchored in practitioner-tier sourcing norms and the Reynolds 2021⁴ murine translation window.
Timing and Pairing
Training-day MOTS-c, morning NAD+.
| Compound | Best time | Pair with | Avoid |
|---|---|---|---|
| MOTS-c | 30–60 min before training | Zone-2 cardio, moderate-intensity sessions | Max-effort intervals, exhaustive endurance bouts |
| NAD+ | Morning, after waking | Hydration, electrolytes | Evening dosing, late-day caffeine stacking |
What to Expect — Timeline
NAD+ is the fastest readout — substrate availability rises within hours, and the acute deficit starts closing immediately. MOTS-c acts mechanistically from the first dose, but mitochondrial build-out compounds over weeks.
| Window | What's happening | What you notice |
|---|---|---|
| Weeks 1–2 | NAD+ substrate replacement | Steadier baseline energy, fewer afternoon crashes |
| Weeks 3–6 | MOTS-c-driven mitochondrial biogenesis | Cardio easier, recovery faster, metabolic flexibility steadier |
| Weeks 7–8 | NAD+-dependent repair programs compound | Better sleep, mental clarity, stable deep energy |
| Weeks 9–12 | Consolidation | Higher training capacity, stable recovery under stress |
Side Effects and Safety
NAD+. Rapid IV push can cause flushing, chest pressure, and transient blood pressure shifts — resolved by slowing the infusion. Hydration before dosing reduces the flushing profile. No serious adverse events have been reported in medical literature from pure NAD+ infusions at standard rates, but the cardiovascular load is real. Patients with heart failure, significant arrhythmia history, or recent cardiac events should get cardiology clearance before starting injectable NAD+, or use oral precursors (NMN or NR) instead.
MOTS-c. Injection-site reactions are the commonly reported issue at SubQ doses, reduced by isotonic bacteriostatic water. Reynolds 2021⁴ reports no systemic safety signals in long-term murine administration. No published human trial tests 12-week-plus safety at the 5–10 mg SubQ dose range in use here. The absence of long-duration human data is a real gap.
MTHFR carriers. MOTS-c inhibits the folate cycle, affecting both purine synthesis (AICAR → AMPK activation) and methylation (5-methyltetrahydrofolate and methionine both drop). MTHFR variants (C677T, A1298C) reduce the methyl-donor supply both pathways draw on, so MOTS-c can produce a sharper energy crash in carriers. The compound isn't off-limits for MTHFR carriers, but carriers should start at 2–3 mg weekly rather than 5–10 mg 2–3× weekly, and pair with methyl donors (methylfolate 400–800 mcg, methylcobalamin 1–2 mg, glycine 3 g) starting the week before the first dose.
Contraindications and cautions. Active malignancy is a theoretical concern given NAD+'s role in supporting cell metabolism broadly; the clinical literature on NAD+ / cancer interaction is mixed. Uncontrolled hypertension, acute infection, and concurrent chemotherapy regimens that work by depleting NAD+ are additional reasons to pause and resolve before starting.
Neither MOTS-c nor injectable NAD+ is FDA-approved for energy or metabolic indications. Absence of approval reflects patent economics rather than a safety verdict — no sponsor has run the Phase 3 trial the FDA would require. Apply the same evidence scrutiny to these compounds as to any prescription drug: read the mechanistic case, weigh the evidence gap, and make an informed decision with a clinician before self-injecting. Nothing in this article is medical advice.
FAQ
Can you take MOTS-c and NAD+ together?
Yes. MOTS-c signals adaptation and raises the speed limit on NAD+ recycling (NAMPT upregulation²). NAD+ supplementation provides the substrate that same system consumes. There is no documented interaction between the two. Wan 2023² and Mohtashami 2022⁵ anchor the direct mechanistic evidence; Pencina 2023⁶ provides the clinical case for why pairing matters rather than using either alone.
Inject separately — some practitioners combine into one syringe, most split into two sites.
How much NAD+ should I take with MOTS-c?
100–200 mg IM or SubQ, daily to 5× per week during the first two loading weeks, dropping to 100–150 mg 3× per week from week seven onward. Pair with 5–10 mg MOTS-c SubQ 2–3× per week across the full cycle. The complete phase-by-phase schedule is in the Protocol section above.
Oral NAD+ precursors — nicotinamide mononucleotide (NMN) at 500–1,000 mg/day or nicotinamide riboside (NR) at 300–600 mg/day — are secondary alternatives. Weaker felt effect at equivalent monthly cost, better suited as a maintenance layer than as an injectable replacement during loading.
When should I take NAD+ and MOTS-c?
MOTS-c 30–60 minutes before zone-2 cardio on training days. NAD+ in the morning. Avoid late-evening NAD+ dosing — it can extend alertness past the morning window through clock-linked enzyme activity (SIRT1⁵). Avoid pairing MOTS-c with max-effort or exhaustive single-bout sessions; moderate-intensity cardio raises MOTS-c in the brain's metabolic-control center (hypothalamus), exhaustive bouts do not (Kang 2021⁷).
I'm on a GLP-1 — can I add this protocol?
Yes, and this is a core use case for the pair. Semaglutide, tirzepatide, and retatrutide all drive aggressive fat mobilization that increases NAD+ demand — converting fat to ATP consumes NAD+ at every step. MOTS-c addresses the mitochondrial capacity strain, NAD+ keeps the fat-burning pathway running. Inject MOTS-c and NAD+ separately from the GLP-1 — different sites, different syringes. Retatrutide users are covered in depth at the retatrutide + NAD+ protocol.
How long until I feel it?
NAD+ shifts felt energy in the first 1–2 weeks as substrate replacement closes the acute deficit. MOTS-c-driven adaptation compounds across the rest of the cycle — see the timeline table for the week-by-week breakdown.
What if I don't notice any change by week 6?
Non-response at week 6 signals the phenotype isn't signal-and-fuel deficit. The most common explanations are sleep or thyroid dysfunction that wasn't the actual limiter, advanced mitochondrial damage beyond what this pair addresses, or K14Q MOTS-c variant blunting the signal. Revisit baseline labs, confirm sleep architecture, and consider whether structural mitochondrial intervention is indicated rather than extending the cycle.
Related Topics
- NAD+ Guide — complete NAD+ overview, injectable vs oral trade-offs, deep mechanism
- MOTS-c Guide — single-compound MOTS-c guide, mechanism, dosing detail
- Why GLP-1 Medications Make You Tired — the fatigue mechanism this pair addresses
- Retatrutide + NAD+ Protocol — retatrutide-specific implementation with NAD+ built in
- Reconstitution Guide — vial prep, bacteriostatic water selection, storage
- Peptide Dosing Calculator — reconstitution math per vial
SS-31 (elamipretide) targets mitochondrial membrane structure rather than signaling or substrate — relevant for Barth syndrome, cardiomyopathy with bioenergetic failure, and advanced mitochondrial disease contexts. See Mito Stack Protocol for the three-compound SS-31 + MOTS-c + NAD+ protocol.
References
¹ AMPK activation — MOTS-c inhibits the folate cycle, causing AICAR accumulation; AICAR activates AMPK. Folate-cycle inhibition also lowers 5-methyltetrahydrofolate and methionine, affecting methylation: Lee C, et al. Cell Metab 2015. doi:10.1016/j.cmet.2015.02.009; Wan W, et al. J Transl Med 2023. doi:10.1186/s12967-023-04128-0
² NAMPT upregulation — MOTS-c increases nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the NAD+ salvage pathway: Wan W, et al. J Transl Med 2023. doi:10.1186/s12967-023-04128-0
³ MOTS-c / CK2 binding — MOTS-c directly binds casein kinase 2; the K14Q variant has reduced binding and tracks with sarcopenia and type 2 diabetes risk in men: Kumagai H, et al. iScience 2024. doi:10.1016/j.isci.2024.108735
⁴ Age-independent physical capacity — MOTS-c improves physical performance in young (2 mo), middle-aged (12 mo), and old (22 mo) mice: Reynolds JC, et al. Nat Commun 2021. doi:10.1038/s41467-020-20790-0
⁵ NAD+ / SIRT1 coupling — MOTS-c elevates intracellular NAD+; SIRT1 deacetylation requires NAD+ availability: Mohtashami Z, et al. 2022. PMID:36482538
⁶ NAD+ precursor limitation in obese cohorts — nicotinamide riboside raised NAD+ but did not improve insulin resistance in obese middle-aged adults: Pencina KM, et al. J Clin Endocrinol Metab 2023. doi:10.1210/clinem/dgad027
⁷ Exercise-intensity dependence — moderate-intensity cardio increases hypothalamic MOTS-c; exhaustive single-bout sessions do not: Kang GM, et al. Cell Metab 2021. doi:10.1016/j.cmet.2021.01.003
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.